A multicenter, open-label, single-arm phase II trial evaluating maintenance of trastuzumab and pertuzumab after trastuzumab deruxtecan as induction therapy for patients with HER2-positive, locally recurrent or metastatic unresectable breast cancer (DEMETHER).